Outlook Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q3 2015 to Q3 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Outlook Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q3 2015 to Q3 2023.
  • Outlook Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending September 30, 2023 was $120M, a 16.7% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2023 $120M +$17.1M +16.7% Sep 30, 2023 10-K 2023-12-22
Q3 2022 $103M +$21.2M +26% Sep 30, 2022 10-K 2023-12-22
Q3 2021 $81.4M +$16.3M +25.1% Sep 30, 2021 10-K 2022-12-29
Q3 2020 $65.1M -$3.87M -5.6% Sep 30, 2020 10-K 2021-12-23
Q3 2019 $69M +$7.07M +11.4% Sep 30, 2019 10-K 2020-12-23
Q3 2018 $61.9M -$8.01M -11.5% Sep 30, 2018 10-K 2019-12-19
Q3 2017 $69.9M +$17.2M +32.5% Sep 30, 2017 10-K 2018-12-18
Q3 2016 $52.7M +$14M +36.3% Sep 30, 2016 10-K 2017-12-29
Q3 2015 $38.7M Sep 30, 2015 10-K 2016-12-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.